EXTENSIVE STAGE SMALL CELL LUNG CANCER

This early-phase trial is testing a new drug called tarlatamab, given together with standard chemotherapy and an immunotherapy, for people with extensive-stage small cell lung cancer who have not had prior treatment. The main goal is to see if the combination is safe and tolerabl…

This phase 3 trial tests whether adding tarlatamab to durvalumab helps people with extensive-stage small-cell lung cancer live longer than durvalumab alone. About 563 participants who have already completed initial chemotherapy plus durvalumab will be randomly assigned to one of …

This study planned to test a combination of two drugs—tarlatamab and sacituzumab govitecan—in adults with extensive-stage small cell lung cancer or extrapulmonary neuroendocrine cancer that had returned or not responded to prior treatment. The goal was to find a safe dose and see…

This study tests a drug called tarlatamab in 32 Chinese adults with advanced small cell lung cancer that has worsened after at least two prior treatments. The main goal is to see if the drug can shrink tumors. This is a Phase 2 trial, meaning researchers are checking both effecti…

This study tests a new drug called HCB101 given together with other cancer treatments for people with advanced solid tumors that have not responded well to prior therapy. About 500 adults will take part to find the safest dose and see if the combination can shrink tumors. The goa…

This study tests a drug called MGC018 in people with extensive-stage small-cell lung cancer that has come back or not responded to treatment. The main goal is to see if the drug can shrink tumors in at least 25% of participants. Patients receive the drug through an IV every 28 da…

This study tests a new drug called BNT327 combined with chemotherapy for people with a fast-growing type of lung cancer (small-cell lung cancer) that has spread or come back. About 110 adults will take part to see if the combo is safe and shrinks tumors. The goal is to better con…

This study compares a new drug, serplulimab, combined with chemotherapy, against an existing drug, atezolizumab, also with chemotherapy, for people with extensive-stage small cell lung cancer who haven't had treatment before. The goal is to see which combination works better at c…

This phase 2 trial is testing a new approach for people with extensive-stage small cell lung cancer who have not had prior treatment. It combines low-dose radiation with standard chemotherapy (cisplatin or carboplatin plus etoposide) and the immunotherapy drug serplulimab. The go…

This study tests a radioactive drug called Lutathera added to standard chemotherapy and immunotherapy for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to find a safe dose and see if the combination helps people live longer. About 24 participants…

This study tested a new treatment for people with extensive-stage small cell lung cancer, a fast-growing type of lung cancer that has spread. The treatment combined low-dose radiation, an immunotherapy drug (durvalumab), and standard chemotherapy. The goal was to see if this comb…

This early-stage study aimed to test a new combination treatment for people with extensive-stage small cell lung cancer who had not received prior therapy. The approach combined low-dose radiation with standard chemotherapy and two immunotherapy drugs (toripalimab and tifcemalima…

This study tests a personalized vaccine (made from each patient's unique tumor markers) combined with the immunotherapy drug durvalumab for people with extensive-stage small cell lung cancer. The goal is to see if this combination is safe and can help slow cancer growth. Only 6 p…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) in people with advanced small cell lung cancer that has spread and has been treated before. The drug is designed to target and kill cancer cells while sparing healthy ones. The goal is to see if it can shrink tumors…

This early-stage trial tests the safety of combining precise radiation (SBRT) with immunotherapy (durvalumab) and two chemotherapy drugs (platinum and etoposide) for people with extensive-stage small cell lung cancer that has stopped responding to platinum chemo. The study aims t…